Edition:
United States

Tonix Pharmaceuticals Holding Corp (TNXP.OQ)

TNXP.OQ on NASDAQ Stock Exchange Global Market

0.52USD
16 Nov 2018
Change (% chg)

$0.01 (+1.27%)
Prev Close
$0.51
Open
$0.52
Day's High
$0.55
Day's Low
$0.48
Volume
455,599
Avg. Vol
171,613
52-wk High
$5.10
52-wk Low
$0.48

Latest Key Developments (Source: Significant Developments)

Tonix Pharmaceuticals Announces Design Of Upcoming Phase 3 Study Of Tonmya For PTSD Following FDA Meeting
Wednesday, 31 Oct 2018 07:00am EDT 

Oct 31 (Reuters) - Tonix Pharmaceuticals Holding Corp ::TONIX PHARMACEUTICALS ANNOUNCES DESIGN OF UPCOMING PHASE 3 STUDY OF TONMYA FOR PTSD FOLLOWING FDA MEETING.TONIX PHARMACEUTICALS - NEW PHASE 3 TRIAL OF TONMYA FOR TREATMENT OF PTSD TO COMMENCE Q1 2019.TONIX PHARMACEUTICALS - A NEW DESIGN FEATURE OF 12-WEEK TONMYA STUDY IS TO INCLUDE CIVILIANS WHO HAVE EXPERIENCED CIVILIAN TRAUMA.TONIX PHARMACEUTICALS - FOR TONMYA STUDY, TO RECRUIT ONLY PARTICIPANTS WHO EXPERIENCED INDEX TRAUMA LESS THAN/EQUAL TO 9 YRS FROM DATE OF SCREENING.  Full Article

Tonix Pharmaceuticals Posts Q1 Loss Of $0.88 Per Share
Monday, 14 May 2018 07:00am EDT 

May 14 (Reuters) - Tonix Pharmaceuticals Holding Corp ::TONIX PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES PROGRAMS UPDATE.Q1 LOSS PER SHARE $0.88.TOPLINE RESULTS FROM FULL PHASE 3 HONOR STUDY OF 550 PARTICIPANTS ANTICIPATED IN Q1 OF 2019.  Full Article

Tonix Pharma Ready To File For Approval Of PTSD Treatment In 2019 Based On Study Data
Tuesday, 3 Apr 2018 07:00am EDT 

April 3 (Reuters) - Tonix Pharmaceuticals Holding Corp ::TONIX PHARMACEUTICALS ACHIEVES 50 PERCENT ENROLLMENT IN PHASE 3 TRIAL OF FDA-DESIGNATED BREAKTHROUGH THERAPY TONMYA® (CYCLOBENZAPRINE HCL SUBLINGUAL TABLETS) FOR THE TREATMENT OF PTSD.TONIX PHARMACEUTICALS HOLDING CORP - ‍TOPLINE RESULTS OF ABOUT 550 PARTICIPANTS WITH MILITARY-RELATED PTSD EXPECTED IN Q4 2018​.TONIX PHARMACEUTICALS HOLDING - ‍PHASE 3 HONOR STUDY ENROLLMENT CONTINUES & INTERIM RESULTS OF FIRST 50 PERCENT OF PARTICIPANTS EXPECTED IN Q3 2018​.TONIX PHARMACEUTICALS - EVIDENCE FROM PHASE 2 STUDY OF TONMYA SHOWED POTENTIAL IMPROVEMENT OVER EXISTING THERAPIES USED TO TREAT MILITARY-RELATED PTSD​.TONIX PHARMACEUTICALS HOLDING CORP - CO IS READY TO FILE NDA FOR TONMYA FOR TREATMENT OF PTSD IN 2019 IN EVENT OF A PERSUASIVE OUTCOME OF HONOR STUDY​.  Full Article

Baker Bros Advisors LP Reports 8.9 Pct Passive Stake In Tonix Pharmaceuticals Holding As Of Dec 31, 2017 - SEC Filing
Tuesday, 13 Feb 2018 04:48pm EST 

Feb 13 (Reuters) - Tonix Pharmaceuticals Holding Corp ::BAKER BROS ADVISORS LP REPORTS 8.9 PERCENT PASSIVE STAKE IN TONIX PHARMACEUTICALS HOLDING AS OF DEC 31, 2017 - SEC FILING.  Full Article

Tonix Pharmaceuticals Completes Positive Pre-Ind Meeting With FDA For TNX-102 SL
Tuesday, 12 Dec 2017 07:00am EST 

Dec 12 (Reuters) - Tonix Pharmaceuticals Holding Corp ::TONIX PHARMACEUTICALS COMPLETES POSITIVE PRE-IND MEETING WITH FDA FOR TNX-102 SL (CYCLOBENZAPRINE HCI SUBLINGUAL TABLETS) AS A CLINICAL CANDIDATE FOR AGITATION IN ALZHEIMER’S DISEASE.PLAN TO SUBMIT TNX-102 SL IND FOR AGITATION IN ALZHEIMER'S DISEASE IN Q1 OF 2018.  Full Article

Tonix Pharmaceuticals Q3 loss per share $0.77
Tuesday, 7 Nov 2017 07:00am EST 

Nov 7 (Reuters) - Tonix Pharmaceuticals Holding Corp :Tonix Pharmaceuticals reports third quarter 2017 financial results and provides programs update.Q3 loss per share $0.77.Tonix Pharmaceuticals Holding Corp - ‍at September 30, 2017, Tonix had cash and cash equivalents of $29.3 million​.  Full Article

Tonix Pharma reports outcomes from CMC guidance meeting with FDA on Tonmya
Tuesday, 17 Oct 2017 07:00am EDT 

Oct 17 (Reuters) - Tonix Pharmaceuticals Holding Corp :Tonix Pharmaceuticals reports outcomes from U.S. FDA breakthrough therapy CMC guidance meeting of Tonmya® (cyclobenzaprine hci sublingual tablets) for PTSD.Tonix Pharmaceuticals Holding Corp - ‍proposed CMC data package to support Tonmya's NDA and commercial manufacturing plans was accepted by FDA​.Tonix Pharmaceuticals Holding - ‍FDA official minutes reflect co's readiness to manufacture Tonmya commercial product at production scale​.Tonix Pharmaceuticals Holding - ‍Tonmya has been conditionally accepted by FDA as proposed trade name for TNX-102 SL (cyclobenzaprine hcl sublingual tablets) for PTSD​.  Full Article

Tonix Pharmaceuticals Holding reports Q2 loss per share $0.65
Monday, 14 Aug 2017 07:00am EDT 

Aug 14 (Reuters) - Tonix Pharmaceuticals Holding Corp :Tonix Pharmaceuticals reports second quarter 2017 financial results and provides programs update.Q2 loss per share $0.65.  Full Article

Tonix Pharmaceuticals files for a mixed shelf of up to $150 mln
Friday, 11 Aug 2017 05:02pm EDT 

Aug 11 (Reuters) - Tonix Pharmaceuticals Holding Corp :Tonix Pharmaceuticals Holding Corp files for a mixed shelf of up to $150 million - SEC filing‍​.  Full Article

Tonix Pharmaceuticals reports conditional acceptance of Tonmya as proposed brand name for TNX-102 SL
Thursday, 6 Jul 2017 07:00am EDT 

July 6 (Reuters) - Tonix Pharmaceuticals Holding Corp ::Tonix Pharmaceuticals Holding Corp- U.S. FDA conditionally accepted proposed trade name Tonmya for tnx-102 sl for management of ptsd.Tonix Pharmaceuticals Holding-topline results expected to be reported in 2h of 2018 from phase 3 honor study of tonmya in military-related ptsd.Tonix Pharmaceuticals Holding Corp- request for proprietary name review for tonmya will be submitted once ptsd new drug application is submitted.Tonix Pharmaceuticals Holding - request for review of tonmya as proposed name for tnx-102 sl for management of fibromyalgia has been withdrawn at FDA.  Full Article